RMDResMed

$230.03-15% 1Y
Latest close: back above its 200-day averageOct 9, 2026what changed →

Is it safe?

Good

Strong, no red flags: a safe balance sheet, clean books, and quality strong.

4 good, 2 neutral
SurvivalSafe zone

Financially healthy, low distress risk Altman Z-score, a bankruptcy-risk model from five balance-sheet ratios.

Honest booksLow risk

Reported earnings show no manipulation flags Beneish M-score, a forensic model that detects earnings-manipulation patterns (receivables outrunning sales, margins slipping, accrual-heavy profit).

Quality7 / 9

High fundamental quality Piotroski F-score, nine pass/fail tests of year-over-year financial health across profitability, balance sheet and efficiency. 7 to 9 is strong, 0 to 3 weak.

Insider conviction-$4.2M

Insiders were net sellers (-$4.2M, 90 days to Oct 8, 2026), selling is often routine.

Credit gradeAAderived · Jun 30, 2026

Net cash and profitable. A rule of thumb on leverage, not a credit rating.

Drawdown risk28% volderived · Oct 9, 2026

Moderate price swings, typical volatility. Worst drawdown -54% · now 18% below its 52-week high.

Unless marked, from SEC EDGAR, as of Jun 30, 2025.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

Volatilitybetter than 82% of the market
Max drawdownbetter than 70% of the market

Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.

Can RMD take a bad year?

ResMed holds $810M more cash than debt, so a bad year is a question about profits, not about lenders.

$810M

Net cash

Net debt / EBITDA
net cash

Net debt / EBITDA · no net borrowings to measure against earnings

Altman Z-score
10.48

Altman Z-score · safe zone, above 3

Debt / equity
0.10×

Debt / equity

Details›
Total debtQ4 2026
$659M
Cash and short-term investments
$1.47B
Net cash
$810M
EBITDA, trailing twelve months
$2.09B
Operating profit, trailing twelve months
$1.89B
Debt / equity
0.10×
Total debt / EBITDA
0.32×
Annualised volatilitytwo years of daily moves
28%
Worst drawdown on file
−54%
Below its 52-week high
18%

Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.